182 related articles for article (PubMed ID: 7545222)
1. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
[TBL] [Abstract][Full Text] [Related]
2. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?
Bennett CL; Golub R; Waters TM; Tallman MS; Rowe JM
Cancer Invest; 1997; 15(3):227-36. PubMed ID: 9171857
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.
Nghiem VT; Vaidya R; Lyman GH; Hershman DL; Ramsey SD; Unger JM
Value Health; 2020 Dec; 23(12):1653-1661. PubMed ID: 33248521
[TBL] [Abstract][Full Text] [Related]
6. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
8. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
13. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.
Jaakkimainen L; Goodwin PJ; Pater J; Warde P; Murray N; Rapp E
J Clin Oncol; 1990 Aug; 8(8):1301-9. PubMed ID: 2166142
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis in phase III clinical cancer trials.
Bennett CL; Armitage JL; Buchner D; Gulati S
Cancer Invest; 1994; 12(3):336-42. PubMed ID: 8187012
[TBL] [Abstract][Full Text] [Related]
15. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
Evans WK; Coyle D; Gafni A; Walker H;
Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
17. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Hornberger J; Hirsch FR; Li Q; Page RD
Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
19. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
20. Cancer trial enrollment after state-mandated reimbursement.
Gross CP; Murthy V; Li Y; Kaluzny AD; Krumholz HM
J Natl Cancer Inst; 2004 Jul; 96(14):1063-9. PubMed ID: 15265967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
